Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
The company is on track for early 2025 approval ... This post was written by Melanie Riehl Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows ...
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback